AstraZeneca Names New CFO Amidst Falling Sales And Profits

Mani

Published onOctober 31, 2013

Updated on May 13, 2021

AstraZeneca plc (NYSE:AZN) (LON:AZN) named a new chief financial officer amidst reporting a sharp fall in its third-quarter sales and profits.

Table of Contents

Drug maker AstraZeneca plc (NYSE:AZN) (LON:AZN) reported earnings per share of $1.21, falling short of analysts’ estimates of $1.27.

Marc Dunoyer to replace Simon Lowth

Simon Lowth, AstraZeneca’s former CFO, announced his departure in July to take up the same position at BG Group plc. Lowth held the position of CFO of the Anglo-Swedish pharmaceuticals group since 2007. He served as interim CEO...

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Mani

Mani is a Senior Financial Consultant. He has worked in Senior Management role in large banking, financial and information technology organizations. He has provided solutions for major banking and securities firms across the globe in the area of retail, corporate and investment banking. He holds MBA (Finance) and Professional Management Accounting Qualifications. His hobbies are tracking global financial developments and watching sports

AstraZeneca Names New CFO Amidst Falling Sales And Profits

Marc Dunoyer to replace Simon Lowth

Login required to continue reading.

Get Your Business News